MitoTracker and JC1-based flow cytometry assays further demonstrated that the presence of TXNIP decreased mitochondrial mass and mitochondrial membrane potential (Fig. 5V, W), suggesting TXNIP suppression of glucose metabolism confers mitochondrial dysfunction in imatinib-resistant CML cells. Here, TXNIP is linked to chronic myelogenous leukemia, BCR-ABL1 positive.